ライフサイエンスコーパス: disability

1 ge and free of documented CVD, dementia, and disability.

2 and disease course, leading to irreversible disability.

3 nic epilepsy with hypotonia and severe motor disability.

4 econd PNs (PN1 and PN2) in MS, with clinical disability.

5 to dementia, a major cause of morbidity and disability.

6 mortality, dementia, or persistent physical disability.

7 Stroke is a leading cause of death and disability.

8 aetiology of Zbtb11-associated intellectual disability.

9 in the pathogenesis of ASD and intellectual disability.

10 Stroke is a leading cause of permanent disability.

11 of change in brain-PAD related to worsening disability.

12 d as a cause of severe X-linked intellectual disability.

13 bidity rates, prolonged hospitalization, and disability.

14 se of death worldwide and a leading cause of disability.

15 eral neuropathy with or without intellectual disability.

16 ead to reduced muscle endurance and physical disability.

17 global mortality and a major contributor to disability.

18 and does not always accommodate people with disability.

19 nels, resulting in epilepsy and intellectual disability.

20 in treatment, adding to the initial cost and disability.

21 nd endovascular thrombectomy shown to reduce disability.

22 36.6%); 72 (11.1%) died or experienced a new disability.

23 y would be associated with reduced long-term disability.

24 stroke is the main cause of long-term adult disability.

25 uding often severe epilepsy and intellectual disability.

26 s, IL-6 and IL-17 are associated with severe disability.

27 associated with both cognitive and clinical disability.

28 nd falls, is a leading cause of neurological disability.

29 th autism spectrum disorder and intellectual disability.

30 edict individuals at highest risk of ongoing disability.

31 lipid metabolism contributes to intellectual disability.

32 in people with MS and are closely related to disability.

33 isability, even with correction for baseline disability.

34 Depression is a leading cause of disability.

35 (TBI) is a leading global cause of death and disability.

36 epilepsy associated with severe intellectual disability.

37 FXS), the most common inherited intellectual disability.

38 umanity and are a leading cause of death and disability.

39 uring the neonatal period leads to long-term disabilities.

40 rience persistent physical and psychological disabilities.

41 sensory dysfunction and severe intellectual disabilities.

42 ms may provide novel therapeutic targets for disability accrual in multiple sclerosis.

43 ficant in chronic MS, likely contributing to disability accrual.

44 tatus report on the incidence, mortality and disability-adjusted life years (DALYs) associated with k

45 nd (2016); disability weights for estimating disability-adjusted life years (DALYs) from the Global B

46 Based on funding per 2017 disability-adjusted life years (DALYs), HIV/AIDS receive

47 sease, along with the attributable number of disability-adjusted life years (DALYs).

48 Severe trauma is the first cause of disability-adjusted life years worldwide, yet most atten

49 a cost-effectiveness threshold of US$500 per disability-adjusted life-year (DALY) averted for our mai

50 $3000 in Colombia, and $1000 in Ukraine) per disability-adjusted life-year averted were considered co

51 used the model to estimate overall cost and disability-adjusted life-years (DALYs) associated with a

52 n terms of cervical cancer cases, deaths, or disability-adjusted life-years (DALYs) averted per 1000

53 Disability-adjusted life-years (DALYs) for fetal loss or

54 Disability-adjusted life-years (DALYs) were calculated a

55 life lost, years lived with disability, and disability-adjusted life-years (DALYs), for cancer overa

56 as summarised with age-standardised rates of disability-adjusted life-years (DALYs), for geographical

57 ation model to estimate net country-specific disability-adjusted life-years (DALYs), years lived with

58 the disease costs averted, with the cost per disability-adjusted life-years averted being less than $

59 4 million people and results in 10.5 million disability-adjusted life-years lost globally.

60 isk factor-1.5 million deaths and 33 million disability-adjusted life-years worldwide are attributabl

61 elfare Loss (WL) was calculated by measuring disability-adjusted-life-years lost to breast cancer alo

62 itive impairment (PSCI) is a major source of disability, affecting up to two thirds of stroke survivo

63 ars of disease onset is associated with less disability after 6-10 years than when commenced later in

64 ill populations and were related to physical disability after extracorporeal membrane oxygenation.

65 e causes neurological deficits and long-term disability after spinal cord injury (SCI).

66 Cognitive impairment is a key cause of disability after traumatic brain injury (TBI) but relati

67 ally and is the leading cause of illness and disability among adolescents.

68 o infection, is a leading cause of death and disability among children worldwide.

69 dhood muscle diseases associated with severe disabilities and early mortality for which there are no

70 velopmental disorders including intellectual disabilities and epilepsies.

71 a patient with prominent speech and language disabilities and identify plausible mechanisms of pathol

72 Autism Spectrum Disorder (ASD), intellectual disabilities and Phelan-McDermid syndrome.

73 was associated with lower risks for physical disability and all cardiovascular outcomes.

74 cute ischemic stroke is the leading cause of disability and among the leading causes of mortality wor

75 both a medical condition that gives rise to disability and an example of human variation that is cha

76 3-5), which is associated with severe mental disability and autism-like symptoms that affect girls du

77 cific biological information of intellectual disability and CHD by conducting systems biology analyse

78 ourse, and the co-occurrence of frailty with disability and cognitive impairment in survivors of crit

79 se may be beneficial for preventing physical disability and CVD but not beneficial for prolonging dis

80 henne muscular dystrophy (DMD) causes severe disability and death of young men because of progressive

81 mains one of the leading causes of permanent disability and death worldwide.

82 cartilage degradation, ultimately leading to disability and decrease of quality of life.

83 s been recognized as a predominant driver of disability and disease progression in central nervous sy

84 his proposed monogenic cause of intellectual disability and epilepsy remain unresolved.

85 reported to be associated with intellectual disability and epilepsy; the functional effects of those

86 blic health hazard for the causation of high disability and eventual morbidity cases with stable prev

87 symptoms, life impact (ie, quality of life, disability and general functioning) and health economics

88 21, we have learned much about intellectual disability and genetic risk factors for congenital heart

89 are common and result in significant patient disability and health care expenditure.

90 flammatory condition characterized by severe disability and high levels of infected white blood cells

91 creasingly recognized major cause of chronic disability and is commonly found in patients with chroni

92 a subgroup with higher rates of intellectual disability and larger cerebral volumes, may be underrepr

93 Given its chronicity, contribution to disability and morbidity, and prevalence of more than 2%

94 ous system disease (NSD) is a major cause of disability and mortality.

95 KDM4B are associated with GDD/ intellectual disability and neuroanatomical defects.

96 stature and variable degree of intellectual disability and neurological features as the core symptom

97 notype, with high prevalence of intellectual disability and optic nerve atrophy/hypoplasia.

98 al palsy, feeding difficulties, intellectual disability and other neurological and behavioural anomal

99 l therapy for recent-onset sciatica improved disability and other outcomes compared with UC.

100 in a recognizable syndrome with intellectual disability and signature brain and congenital abnormalit

101 or depressive disorder is a leading cause of disability and significant mortality, yet mechanistic un

102 tations were present, including intellectual disability and spasticity.

103 rological disorders are the leading cause of disability and the second leading cause of death worldwi

104 patients typically have substantial residual disability and unique long-term rehabilitation needs.

105 ipants survived major surgery with increased disability and were monitored on a monthly basis for 6 m

106 tors for future low back pain (LBP) -related disability and work loss respectively.

107 expect to live up to 11 years longer without disability and, up to 12 years longer without chronic co

108 e common phenotypic features of intellectual disability and/or global developmental delay; hypotonia;

109 n mitigate the progression to heart failure, disability, and death.

110 increased risk of various health conditions, disability, and death.

111 tality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs),

112 a disease that results in significant death, disability, and disfigurement around the world.

113 uding autism spectrum disorder, intellectual disability, and epilepsy.

114 individuals with microcephaly, intellectual disability, and epilepsy.

115 ith cancer-related pathologies, intellectual disability, and schizophrenia are increasingly investiga

116 , global developmental delay or intellectual disability, and severe sleep disturbance.

117 iable expression of intellectual or learning disability are common clinical features.

118 Brain abnormalities and intellectual disability are commonly observed in individuals with CHA

119 logy seems more strongly related to physical disability as measured by the Expanded Disability Status

120 t stature, developmental delay, intellectual disability as well as cardiac hypertrophy.

121 ignificant improvement of motor function and disability (as assessed by the Burke Fahn Marsden's Dyst

122 t and reverse the persistent accumulation of disabilities associated with progressive forms of MS (P-

123 tional classification and leprosy-associated disabilities at diagnosis.

124 hysical therapy had less pain and functional disability at 1 year than patients who received an intra

125 nd location within corticospinal tracts, and disability at baseline and 2-year follow-up.

126 respecified secondary outcomes were level of disability at day 90 (modified Rankin Scale [mRS] score;

127 Disability at nadir or recovery did not differ between t

128 -10, with higher scores indicating increased disability), at 6-10 years after disease onset, assessed

129 e been robustly associated with intellectual disability, autism, and schizophrenia.

130 erapies, patients may still face progressive disability because of failure of myelin regeneration and

131 Depression is a leading cause of worldwide disability but there remains considerable uncertainty re

132 or autism spectrum disorder and intellectual disability, but it has not been reported if or how these

133 late a personalised risk of long-term severe disability.Clinicians should select suitable CIS cases f

134 rrying rare mutations linked to intellectual disability contribute to ADHD risk through common geneti

135 uth, developmental delay and/or intellectual disability, corpus callosum agenesis or hypoplasia, flex

136 nsible for a large portion of healthcare and disability costs worldwide.

137 associated with significantly fewer patient disability days at 1 year than did surgery (adjusted mea

138 iated with statistically significantly fewer disability days at 1 year.

139 omplicated pediatric appendicitis with fewer disability days than surgery.

140 e 2 primary outcomes assessed at 1 year were disability days, defined as the total number of days the

141 at 24 months of corrected age, was death or disability, defined as any of cognitive deficit, cerebra

142 s, in clinical populations with intellectual disability, degenerative brain disease, brain injury, ps

143 atures positively loaded by migraine-related disability, depression, poor sleep quality, somatic symp

144 Disability, depressive symptoms, and impaired health-rel

145 in DYRK1A exhibit microcephaly, intellectual disability, developmental delay and/or congenital anomal

146 han with aspirin alone, but the incidence of disability did not differ significantly between the two

147 The incidence of disability did not differ significantly between the two

148 amily genes are also mutated in intellectual disability disorders, and patient-derived SRPK point mut

149 ies in children, with the disease burden and disabilities due to cCMV greater than many other well re

150 jury (TBI) is the leading cause of death and disability due to trauma.

151 MS outcomes; some people accrued substantial disability early on, whereas others ran a more favorable

152 romic forms of NDDs with severe intellectual disability, epilepsy and microcephaly.

153 Elbow pain can cause disability, especially in athletes, and is a common clin

154 fractions correlated with follow-up physical disability, even with correction for baseline disability

155 p, cataract, tooth abnormality, intellectual disability, facial dysmorphism, attention-deficit hypera

156 worldwide and ranking as a leading cause of disability for almost three decades.

157 defects, resulting in permanent neurological disability for one newborn child every hour in the Unite

158 Disability-free life expectancy was estimated using repe

159 ty and CVD but not beneficial for prolonging disability-free survival or avoiding death or dementia.

160 association among statins, dementia-free and disability-free survival, and cardiovascular disease (CV

161 The primary outcome, referred to as "disability-free survival," was a composite of all-cause

162 lasticity may contribute to the intellectual disability frequently seen in BBSOAS.

163 ndary outcomes were measures of neurological disability, functional independence in activities of dai

164 The intellectual disability gene set was significantly associated with AD

165 tic gene panel of 396 autosomal intellectual disability genes were tested for association with ADHD r

166 urological diseases are the leading cause of disability globally.

167 g baseline characteristics, only receiving a disability grant was significantly associated with dual

168 ee OA alone are major contributors to global disability, having notable effects on individual well-be

169 is characteristically displayed intellectual disability, hyperactivity, anxiety, and abnormal sensory

170 obal developmental delay and/or intellectual disability, hypotonia, cerebellar ataxia, cerebellar atr

171 velopmental diseases, including intellectual disability (ID) and autism spectrum disorders (ASD).

172 autism spectrum disorder (ASD), intellectual disability (ID), and schizophrenia (SZ).

173 ental disorder characterized by intellectual disability (ID), motor and speech delay, autistic featur

174 hrough services for people with intellectual disabilities in Cambridge (UK).

175 ading cause of hearing loss and neurological disabilities in children, with the disease burden and di

176 blockers as a new intervention for learning disabilities in FASD.

177 ible overlapping of obesity and intellectual disabilities in several cases.

178 one of the leading causes of death and major disabilities in the elderly worldwide.

179 thologies and are leading causes of pain and disability in adults.

180 opathy (HIE) is a leading cause of death and disability in children.

181 ocker or a glutaminase inhibitor ameliorated disability in experimental neuroinflammation.

182 Physical disability in extracorporeal membrane oxygenation patien

183 l easily useable in daily practice to assess disability in IBD patients.

184 alanine (p.D50A), resulting in intellectual disability in male patients.

185 Disability in multiple sclerosis (MS) is considered prim

186 involvement has a central role in explaining disability in multiple sclerosis (MS): Lesion-induced da

187 Chronic disability in multiple sclerosis is linked to neuroaxona

188 and spinal cord portions to explain physical disability in multiple sclerosis patients, with a predom

189 mptomatic treatment to ameliorate ambulatory disability in multiple sclerosis.

190 m leprae, causes nerve damage, deformity and disability in over 200,000 people every year.

191 aps and individual trajectories of worsening disability in patients with multiple sclerosis (MS).

192 correlation between lesion load and physical disability in patients with multiple sclerosis remains m

193 rheumatoid arthritis (RA), often leading to disability in patients.

194 rompt diagnosis and early treatment prevents disability in Polyneuropathy Organomegaly Endocrinopathy

195 and associations with death and neurological disability in prospective cohorts of Malawian children w

196 Chronic disability in TMJ osteoarthritis (OA) increases with agi

197 most common nontraumatic disease that causes disability in young adults, extensive research has been

198 outcomes including the score on the Owestry Disability Index and pain at 12 months were in the same

199 side, r = 0.627, p = 0.007) and the Oswestry disability index scores in LDH patients.

200 dary outcomes were the score on the Oswestry Disability Index, back and leg pain, and quality-of-life

201 ial and ethnic backgrounds, individuals with disabilities, individuals from disadvantaged backgrounds

202 wed or married, unemployed, or have physical disabilities is cut substantially with greater sameness.

203 Resultant disability is caused by both the dominant clinical prese

204 e (FXS), an X-chromosome linked intellectual disability, is the leading monogenetic cause of autism s

205 nal cord cross-sectional area-a predictor of disability-is poor, questioning the unique role of axona

206 erent aspects of disease activity (relapses, disability, magnetic resonance imaging parameters) up to

207 atosis type 1 for the treatment of cognitive disabilities may have to start at a much younger age tha

208 The primary outcome was disability, measured with the Expanded Disability Status

209 e proportion of patients with progression on disability measures was lower in those who initiated ocr

210 cale-16); secondary outcomes were mortality, disability, medication adherence, depression, cognition,

211 ic etiology in individuals with intellectual disability, microcephaly, and epilepsy.

212 volume, all-cause mortality, death or major disability (modified Rankin Scale (mRS) score >=4) and s

213 ent with a clinical spectrum of intellectual disability, motor delay, speech delay, seizures, hypoton

214 individuals with profound neurodevelopmental disability, muscular hypotonia, feeding abnormalities, r

215 t common diagnoses were significant physical disabilities (n = 100, 64.1%), treatment-resistant tuber

216 recruit general, mental health and learning disability nurses, at different levels of seniority.

217 ced in both groups of children with learning disabilities (NVLD and RD) relative to TD children.

218 rm function was evaluated annually using the Disabilities of the Arm, Shoulder, and Hand; Carroll; Ha

219 asures (PROMs) are commonly used to estimate disability of patients with spinal degenerative disease.

220 d language developmental delay, intellectual disability often associated with early-onset movement di

221 patients with varying levels of WAD-related disability one-year following the motor vehicle collisio

222 ne in seven had frailty without co-occurring disability or cognitive impairment.

223 Safety outcomes included death, severe disability or death (mRS score 4-6), and symptomatic int

224 nsion (OR, 0.97; 95% CI 0.60 to 1.57), major disability or death (OR, 1.05; 95% CI 0.61 to 1.63), all

225 ow Outcome Scale-Extended score >4 [moderate disability or good recovery]) in the combined tranexamic

226 nge, 0-6); mRS score of 0 to 1 (freedom from disability) or no change from baseline at 90 days; mRS s

227 orking years, help is needed due to illness, disability, or bad luck.

228 There were 376 patients with frailty, disability, or cognitive impairment at 3-month follow-up

229 At 12 months, 276 patients had frailty, disability, or cognitive impairment, 37 (13%) of whom ha

230 with age, disease duration, disease course, disability, or disease-modifying treatments.

231 We therefore aimed to compare long-term disability outcomes between patients who started high-ef

232 -controlled study found that MD1003 improved disability outcomes over 12 months in patients with prog

233 MS (n = 37), whose trajectories of worsening disability over the 2 y preceding study entry were calcu

234 e absolute numbers of deaths and people with disabilities owing to neurological diseases have risen s

235 (motor, P = 0.001, P = 0.004, and P = 0.012; disability, P = 0.009, P = 0.002 and P = 0.012).

236 of hospital services, employment, receipt of disability pension, income, days of sick leave, or nursi

237 of hospital services, employment, receipt of disability pension, income, number of sick leave days, a

238 Patients were excluded if they had cognitive disabilities preventing them from following the protocol

239 comes included death or patient-reported new disability (primary); safety incidents, length of stay (

240 d in 3 month (3M) and 6 month (6M) confirmed disability progression (CDP) were evaluated post hoc.

241 D at baseline was associated with more rapid disability progression and the rate of change in brain-P

242 e and younger patients) and resulted in less disability progression for up to 2 years.

243 e primary endpoint of reduction in confirmed disability progression in a phase 3 trial of patients wi

244 duration of therapeutic lag on relapses and disability progression in different therapies in patient

245 of thalamic atrophy is a strong predictor of disability progression.

246 or most of the measures of 24-week confirmed disability progression: EDSS, 51.7% vs 64.8% (difference

247 ned the long-term risks of recurrent stroke, disability, quality of life, dementia and hospital care

248 All had developmental delay or intellectual disability ranging from mild to severe.

249 tic hypothermia for neonatal encephalopathy, disability rates and the severity spectrum of cerebral p

250 % [95% CI, -7.9% to 2.1%]; P = .26), 6-month Disability Rating Scale score (6.8 vs 7.6; difference, -

251 udy reveals that a large set of intellectual disability-related genes contribute to ADHD risk through

252 the number one cause for acquired long-term disability, resulting in a global annual economic burden

253 The primary endpoint, the GBS disability scale at 4 weeks, was assessed with multivari

254 e Motor Score (BFMMS) and Burke-Fahn-Marsden Disability Score (BFMDS).

255 cy maps were produced for each phenotype and disability scores assessed with Expanded Disability Stat

256 disorder characterized by mild intellectual disability, seizures, behavioral abnormalities, and vari

257 Rehabilitation has often been seen as a disability-specific service needed by only few of the po

258 yses revealed a reduced annual relapse rate, disability stabilization, and reduced brain atrophy afte

259 as Annualized Relapse Rate (ARR) or Expanded Disability Status Scale (EDSS) before and after treatmen

260 -modifying treatment and who had an Expanded Disability Status Scale (EDSS) score of 4.0-6.5.

261 Relationships between brain-PAD and Expanded Disability Status Scale (EDSS) were explored.

262 Changes in Expanded Disability Status Scale (EDSS), and in 3 month (3M) and

263 pses, new white matter lesions, and Expanded Disability Status Scale [EDSS] change) were identified.

264 and disability scores assessed with Expanded Disability Status Scale score and pyramidal functional s

265 The baseline Expanded Disability Status Scale score was associated with lesion

266 was the primary determinant of the Expanded Disability Status Scale, white matter lesion fractions i

267 sical disability as measured by the Expanded Disability Status Scale.

268 d had a score of 6.5 or less on the Expanded Disability Status Scale.

269 e was disability, measured with the Expanded Disability Status Score (EDSS; an ordinal scale of 0-10,

270 patients with various disease phenotypes and disability status.

271 obal developmental delay and/or intellectual disability, subtle facial dysmorphisms, behavioral and p

272 Both can lead to lifelong disabilities, such as chronic obstructive pulmonary dise

273 er syndrome (WS), an overgrowth/intellectual disability syndrome (OGID), is caused by pathogenic vari

274 n syndrome (SRS) is an X-linked intellectual disability syndrome caused by a loss-of-function mutatio

275 ventable birth defect and neurodevelopmental disability syndrome.

276 in ligase that is mutated in an intellectual disability syndrome.

277 l disorders, such as autism and intellectual disability, that are characterized by dendritic aberrati

278 9 (0.6%) children, with ASD and intellectual disability the most common combination.

279 ealth, lengthen life, and reduce illness and disability," the US biomedical research enterprise must

280 ies with higher proportions of older adults, disabilities, unemployment, and mobile homes, as well as

281 n from the Health Survey for England (2016); disability weights for estimating disability-adjusted li

282 Population Prospects (UNWPP) 2019 revision, disability weights of the Global Burden of Disease (GBD)

283 Associations between MRI variables and disability were explored with age-, sex- and phenotype-a

284 Only participants with mild or moderate disability were included who had at least one of the fol

285 ics, including severity of pain and level of disability, were similar in the two groups.

286 nal dimensions of patients' life, leading to disability which is essential to quantify as part of Pat

287 pinal cord injury (SCI) is a common cause of disability, which often leads to sensorimotor cortex dys

288 udy included adults aged 35-74 years without disability who were recruited to the China Kadoorie Biob

289 - 7.9; 83% females) with a range of clinical disability, who completed the 6MWT wearing gait analysis

290 XS), a common form of inherited intellectual disabilities with a high risk for ASDs.

291 ecially midface hypoplasia, and intellectual disability with severe expressive language delay.

292 sequent ischemic stroke and the incidence of disability within 30 days.

293 epression represents the number one cause of disability worldwide and is often fatal.

294 ressive disorder (MDD) is a leading cause of disability worldwide, yet current treatment strategies r

295 etal disease and a leading cause of pain and disability worldwide.

296 Ten-year cumulative probabilities of disability worsening and improvement were 27.8% and 33.1

297 Conclusion: A more severe trajectory of disability worsening in MS is associated with innate imm

298 whose mutations cause X-linked intellectual disability (XLID) in humans.

299 the prevalence and years of life lived with disability (YLDs) of 25 diseases, impairments, or bespok

300 djusted life-years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) due to